Efficacy and safety of bismuth‐based quadruple therapy for<i>Helicobacter</i><i>pylori</i>eradication in children
Kallirroi Kotilea, Samy Cadranel, Assaad Salame, Julie Nguyen, Tania Mahler, Véronique Yvette Miendje Deyi, Laurine Verset, Patrick Bontems
Abstract
Abstract Objectives To evaluate the efficacy and safety of a 10‐day quadruple therapy containing colloidal bismuth sub‐citrate (CBS), esomeprazole (ESO), amoxicillin (AMO), and metronidazole (MET) for Helicobacter pylori ( H . pylori ) eradication in children. Methods Monocentric, open‐label, prospective, single‐arm clinical trial in children aged 6–17 years with H . pylori infection. The study was carried out on consecutive patients with upper gastrointestinal symptoms and H . pylori infection confirmed by histology and culture of gastric biopsies. The outcome was evaluated using a 13 C‐urea breath test 8–10 weeks post‐therapy. Adverse events and compliance were evaluated by daily journal and pill counting. Results A total of 36 children fulfilling the inclusion criteria were enrolled. Eight (22.2%) of them had a prior H . pylori eradication treatment. Thirteen (36.1%) patients were infected by a strain resistant to MET and 8 (22.2%) by a strain resistant to both MET and Clarithromycin (CLA). In the intention‐to‐treat population (ITT), eradication was achieved in 35/36 patients ( 95%CI : 85%−99% ). Twenty‐three children reported at least one adverse event (63.8%), mostly mild (nausea, vomiting, abdominal pain, diarrhea, dark stool, metallic taste, headache, and rash). The compliance rate was high, with 30 (83.3%) patients taking >90% of the treatment. Conclusion 10‐day quadruple therapy containing CBS, ESO, AMO, and MET for H . pylori eradication in children is a safe and very effective solution, especially for previously treated patients and those infected with double resistant strains.